Pier Luigi Zinzani, MD, PhD:This is a very important update at 2 years, concerning the real role in terms of long-term activity of copanlisib as a single agent in relapsed/refractory patients in the third line. So, as I said before, the CHRONOS-1 is a registration study. There was an update, and right now there are 11 patients on treatment after more than 2 years in the CHRONOS-1 [trial]. In the CHRONOS-1 trial, we included 117 patients, and they said that right now there are, after more than 2 years, 11 patients on treatment. But the most important thing is that 7 patients had a conversion rate from PR [partial response] to CR [complete response]. So the concept is, if you continue to use copanlisib, you can have also a late response obtaining a real important conversion from PR, partial response, to complete response. It’s a very important concept.
And at 2-year follow-up of patients treated inside the CHRONOS-1 trial, the median duration of the response is quite good in terms of 14.5 months, and the median progression-free survival is more than 1 year, 12.5 monthsvery solid data. And, at the same time, I come back to the concept of conversion rate from PR to CR. Right now, according to this 2-year of update of CHRONOS-1, the CR rate is 17% instead of the 14% with CHRONOS-1, and the overall response rate is 61%—very important data when you come back to this study population of patients heavily pretreated with conventional chemoimmunotherapy.
Transcript edited for clarity.
Behind the FDA Approval of Zanubrutinib and Obinutuzumab in Follicular Lymphoma
March 8th 2024Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
Read More
FDA Grants Priority Review to Epcoritamab for R/R Follicular Lymphoma
February 27th 2024If FDA-approved, epcoritamab would be the first and only subcutaneous bispecific antibody indicated for the treatment of adult patients with relapsed/refractory follicular lymphoma after 2 rounds of previous therapy.
Read More
Second-Line Liso-cel Shows Promise in High-Risk Relapsed/Refractory FL
January 12th 2024In an interview with Targeted Oncology, Franck Morschhauser, MD, PhD, discussed the high complete response rates and durable remissions seen with lisocabtagene maraleucel in patients with high-risk relapsed/refractory follicular lymphoma.
Read More
Pirtobrutinib Monotherapy Demonstrates Early Activity in R/R Follicular Lymphoma
December 11th 2023Treatment with single-agent pirtobrutinib showed encouraging efficacy with a tolerable safety profile in a cohort of heavily pretreated patients with relapsed/refractory follicular lymphoma.
Read More